TY  - JOUR
A1  - Steinhardt, Maximilian J.
A1  - Cejka, Vladimir
A1  - Chen, Mengmeng
A1  - Bäuerlein, Sabrina
A1  - Schäfer, Julia
A1  - Adrah, Ali
A1  - Ihne-Schubert, Sandra M.
A1  - Papagianni, Aikaterini
A1  - Kortüm, K. Martin
A1  - Morbach, Caroline
A1  - Störk, Stefan
T1  - Safety and tolerability of SGLT2 inhibitors in cardiac amyloidosis — a clinical feasibility study
JF  - Journal of Clinical Medicine
N2  - Sodium-glucose transport protein 2 inhibitors (SGLT2i) slow the progression of renal dysfunction and improve the prognosis of patients with heart failure. Amyloidosis constitutes an important subgroup for which evidence is lacking. Amyloidotic fibrils originating from misfolded transthyretin and light chains are the causal agents in ATTR and AL amyloidosis. In these most frequent subtypes, cardiac involvement is the most common organ manifestation. Because cardiac and renal function frequently deteriorate over time, even under best available treatment, SGLT2i emerge as a promising treatment option due to their reno- and cardioprotective properties. We retrospectively analyzed patients with cardiac amyloidosis, who received either dapagliflozin or empagliflozin. Out of 79 patients, 5.1% had urinary tract infections; 2 stopped SGLT2i therapy; and 2.5% died unrelated to the intake of SGLT2i. No genital mycotic infections were observed. As expected, a slight drop in the glomerular filtration rate was noted, while the NYHA functional status, cardiac and hepatic function, as well as the 6 min walk distance remained stable over time. These data provide a rationale for the use of SGLT2i in patients with amyloidosis and concomitant cardiac or renal dysfunction. Prospective randomized data are desired to confirm safety and to prove efficacy in this increasingly important group of patients.
KW  - heart failure
KW  - chronic kidney disease
KW  - amyloidosis
KW  - SGLT2 inhibitors
Y1  - 2024
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-356024
SN  - 2077-0383
VL  - 13
IS  - 1
ER  -